Koninklijke Philips (PHG)
(Delayed Data from NYSE)
$26.28 USD
-0.02 (-0.08%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $26.28 0.00 (0.00%) 4:46 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHG 26.28 -0.02(-0.08%)
Will PHG be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PHG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHG
Philips (PHG) Boosts Precision Diagnosis With AI Platform
Philips (PHG) Boosts Medical Imaging Footprint With New Move
PHG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Here's Why Royal Philips (PHG) is a Strong Value Stock
Other News for PHG
Deep integration of proven AI tools into Philips cardiovascular ultrasound systems to better diagnose more cardiac disease patients
Philips announces next-gen AI-enabled cardiovascular ultrasound platform
Stifel Nicolaus Remains a Buy on Pharming Group (PHGUF)
Analyst Issues Buy Rating on Pharming Group, Foreseeing Success for Leniolisib Despite EU Regulatory Delays
Philips celebrates 1.9m liters of helium saved as it marks 1,111 helium-free MRI operations installs, expanding care to more patients in more locations